@BradLoncar believes it is very underappreciated how much interest rates affect people’s investment decisions and @daphnezohar thinks once the smaller deals pick up, that will be more likely to influence additional M&A activity in the future. #BiotechHangout

On biotech’s M&A environment, @OtelloVC says there’s interest “now that the capital markets have resumed some kind of rational behavior” but “there’s just not a lot of potential targets that make sense and could make a difference for these various buyers who need to sustain quite…

Great list @daphnezohar referenced from BIO (@IAmBiotech) summarizing the areas of interest for top pharma companies #BiotechHangout

Great list @daphnezohar referenced from BIO (@IAmBiotech) summarizing the areas of interest for top pharma companies #BiotechHangout like 1

.@JSchimmer_E highlights $AUTL’s Obe-cel data for B-ALL, which showed comparable efficacy to tecartus with improved safety. “We’re starting to see the emergence of better mousetraps in the cell therapy space.” #BiotechHangout

Are we doing patients a disservice using RESCIST response criteria instead of ctDNA, asks @JSchimmer_E. “We may be missing very active potential therapeutics because we aren’t looking at the right thing.” #BiotechHangout

Check out @bradloncar's interview with $REPL CEO for @BiotechTVHQ: #BiotechHangout

$REPL was the biggest stock mover of #ASCO23, notes @bradloncar, for their data in patients with melanoma. He also highlights Bicara, “a small private company really made some waves trying to compare themselves to Keytruda” #BiotechHangout

$COGT had a great week following positive Phase 3 data presented at #ASCO23 & a $150M offering. @bradloncar notes that in the current market, the best time to raise money is coming off of really positive news like this, otherwise companies are struggling to raise. #BiotechHangout

More #ASCO23 data: $DAWN shared strong results with their therapy to treat pediatric brain cancer. @bradloncar notes the strength of the data will put them in a good position #BiotechHangout

"It's an overnight success story that took 40 years in this case, but we see those a lot," notes @daphnezohar on $IMGN data #BiotechHangout

On $IMGN’s survival data at #ASCO23: “It’s great for the ADC field to have another win under its belt,” says @JSchimmer_E #BiotechHangout

The team discussed @JacobPlieth’s stock-moving tweet regarding $PDSB’s #ASCO23 poster presentation. @bradloncar notes that no one understands and covers oncology better than Jacob & @JSchimmer_E agrees, noting the stock has already bounced back #BiotechHangout

.@daphnezohar notes a surprising acquisition of $PRTK for $462M by Gurnet Point Capital & Novo holdings. @JSchimmer_E adds it was an unexpected acquirer for a company that was expected to be acquired and wonders about the synergies #BiotechHangout

Secondary raises this week from $DAWN, $IONS, $NAMS, $COGT & $VXRT. @OtelloVC notes, “I wouldn’t necessarily stretch that into a trend that will translate necessarily to IPOs. I just think the right companies that are showing good data are able to raise capital." #BiotechHangout

Closing out the topic, @daphnezohar notes, "I think one area where everyone agrees is that out of pocket costs for patients really need to come down. I am encouraged that there is a lot of pressure on PBMs to pass on the discounts and rebates that they get to patients and that is…